Rodrigo Mansur
Clinical Researcher in Affective Disorders
Data updated
Research Footprint
Rodrigo Mansur appears in 13 tracked papers (2018–2025), most studied alongside Ketamine, Psilocybin and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation (676 citations).
Frequent co-authors: Roger McIntyre, Jonathan Rosenblat and Shokouh Meshkat.
Publication Landscape
How the 13 papers Blossom tracks for Rodrigo Mansur line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Rodrigo Mansur's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 13 of 13 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Rodrigo Mansur publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Rodrigo Mansur publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
R. B. Mansur is a clinician–researcher working at the intersection of psychedelic-assisted therapies and rapid-acting pharmacological treatments for mood disorders. Mansur’s recent portfolio centres on clinical trials and real-world studies of psilocybin-assisted psychotherapy for treatment-resistant depression — including investigations of repeated dosing and applications in individuals with bipolar II disorder — alongside pragmatic evaluations of repeated intravenous ketamine infusions in populations characterised by youth, borderline personality disorder comorbidity, and suicidality. Mansur has also contributed to mechanistic clinical research exploring whether sleep changes mediate the antidepressant and anti-suicidal effects of intravenous ketamine.
Mansur’s work emphasises translational clinical design and real-world effectiveness, addressing important clinical questions about safety, applicability across diagnostic comorbidity, dosing strategies, and short-term mechanistic mediators of response. These contributions support the evidence base for integrating psychedelic and rapid-acting interventions into treatment pathways for people with treatment-resistant depressive disorders and complex psychiatric comorbidity.
Key Impact
Notable for clinical research into psychedelic-assisted psychotherapy and rapid-acting antidepressant treatments for treatment-resistant mood disorders, with emphasis on translational and real-world effectiveness studies.
Collaboration Network
29 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Rodrigo Mansur's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Rodrigo Mansur is associated with.
University Health Network, Toronto
Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.
View stakeholder →University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →